Cell Biotech Co. Ltd - Asset Resilience Ratio
Cell Biotech Co. Ltd (049960) has an Asset Resilience Ratio of 54.84% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 049960 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Cell Biotech Co. Ltd's Asset Resilience Ratio has changed over time. See 049960 net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Cell Biotech Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Cell Biotech Co. Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩73.80 Billion | 54.84% |
| Total Liquid Assets | ₩73.80 Billion | 54.84% |
Asset Resilience Insights
- Very High Liquidity: Cell Biotech Co. Ltd maintains exceptional liquid asset reserves at 54.84% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cell Biotech Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Cell Biotech Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pluristem
TA:PSTI |
Biotechnology & Medical Research | 48.26% |
|
Hadasit Bio
TA:HDST |
Biotechnology & Medical Research | 57.00% |
|
Purple Biotech Ltd
TA:KTOV |
Biotechnology & Medical Research | 0.01% |
|
Peptron Inc
KQ:087010 |
Biotechnology & Medical Research | 57.41% |
|
MEDIPOST Co. Ltd
KQ:078160 |
Biotechnology & Medical Research | 0.72% |
|
Bioneer Corporation
KQ:064550 |
Biotechnology & Medical Research | 14.92% |
|
Macrogen Inc
KQ:038290 |
Biotechnology & Medical Research | 3.56% |
|
Panagene Inc
KQ:046210 |
Biotechnology & Medical Research | 0.14% |
Annual Asset Resilience Ratio for Cell Biotech Co. Ltd (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Cell Biotech Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 63.42% | ₩82.70 Billion ≈ $56.04 Million |
₩130.40 Billion ≈ $88.37 Million |
+10.34pp |
| 2023-12-31 | 53.08% | ₩62.45 Billion ≈ $42.32 Million |
₩117.64 Billion ≈ $79.72 Million |
-3.34pp |
| 2022-12-31 | 56.42% | ₩65.36 Billion ≈ $44.29 Million |
₩115.84 Billion ≈ $78.50 Million |
+5.20pp |
| 2021-12-31 | 51.22% | ₩57.82 Billion ≈ $39.18 Million |
₩112.88 Billion ≈ $76.49 Million |
-0.89pp |
| 2020-12-31 | 52.12% | ₩54.88 Billion ≈ $37.19 Million |
₩105.30 Billion ≈ $71.36 Million |
-2.56pp |
| 2019-12-31 | 54.67% | ₩59.21 Billion ≈ $40.13 Million |
₩108.30 Billion ≈ $73.40 Million |
+11.29pp |
| 2018-12-31 | 43.39% | ₩48.61 Billion ≈ $32.94 Million |
₩112.05 Billion ≈ $75.93 Million |
-16.31pp |
| 2017-12-31 | 59.70% | ₩57.59 Billion ≈ $39.03 Million |
₩96.48 Billion ≈ $65.38 Million |
-1.92pp |
| 2016-12-31 | 61.62% | ₩55.78 Billion ≈ $37.80 Million |
₩90.53 Billion ≈ $61.35 Million |
+15.46pp |
| 2015-12-31 | 46.16% | ₩34.61 Billion ≈ $23.45 Million |
₩74.97 Billion ≈ $50.80 Million |
+6.29pp |
| 2014-12-31 | 39.88% | ₩22.97 Billion ≈ $15.57 Million |
₩57.60 Billion ≈ $39.04 Million |
+4.65pp |
| 2013-12-31 | 35.22% | ₩16.45 Billion ≈ $11.15 Million |
₩46.70 Billion ≈ $31.65 Million |
-1.23pp |
| 2012-12-31 | 36.46% | ₩14.69 Billion ≈ $9.96 Million |
₩40.30 Billion ≈ $27.31 Million |
+9.26pp |
| 2011-12-31 | 27.19% | ₩9.99 Billion ≈ $6.77 Million |
₩36.75 Billion ≈ $24.90 Million |
-- |
About Cell Biotech Co. Ltd
Cell Biotech Co., Ltd., a biotechnology company, develops and sells lactic acid bacteria in South Korea. It also offers probiotic products under the Nutra DUOLAC, LACTOClear, and LAB2PRO brands. The company also exports its products to approximately 40 countries, including the United States, Europe, Japan, and China. Cell Biotech Co., Ltd. was founded in 1995 and is based in Gimpo-si, South Korea.